<DOC>
	<DOCNO>NCT03044249</DOCNO>
	<brief_summary>A ten-week study ass MP-101 treatment psychosis participant Alzheimer 's Disease , compare placebo .</brief_summary>
	<brief_title>A Study MP-101 Treatment Psychosis Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<criteria>Females must nonchildbearing potential , defined woman great equal ( ≥ ) 60 year age , postmenopausal woman ≥50 less ( &lt; ) 60 year age cessation menses least 12 month , woman congenitally surgically sterile Males must agree use 2 form highly effective birth control female partner childbearing potential enrol study , least 28 day follow last dose Ambulatory ( without walk device ) stable gait Have document diagnosis probable Alzheimer 's Disease ( AD ) Able communicate verbally Have psychotic symptom develop follow diagnosis probable AD , include visual and/or auditory hallucination , and/or delusion Have NPI score ≥4 either individual item ( delusion hallucination ) ≥6 Psychosis Subscale ( combine delusion hallucination ) Have MiniMental State Examination ( MMSE ) score 10 24 . Have Magnetic Resonance Imaging ( MRI ) compute tomography ( CT ) scan concurrent follow diagnosis probable AD , exclude prior stroke structural brain disease Have reliable caregiver/study informant provide write informed consent participate frequent contact patient ( defined spending least 4 hours/day least 4 days/week patient knowledgeable patient 's daytime nighttime behavior ) . The caregiver/study informant must able communicate site personnel , opinion investigator , must understand write protocolspecified questionnaire . If caregiver/study informant continue , replacement caregiver allow criterion meet Are receive acetylcholinesterase inhibitor ( AChEIs ) stable dos ≥3 month prior study , opinion investigator likely remain stable treatment regimen 6 month . Patients treat AChEIs also eligible study enrollment Have venous access sufficient allow blood sample per protocol Have clinical laboratory test result within normal reference range population investigative site Are capable participate study assessment Are able willing provide consent ( patient caregivers/study informant ) Have history significant psychotic disorder prior simultaneous probable diagnosis AD ( include , limited , schizophrenia bipolar affective disorder ) Meet National Institute Neurological Disorders Stroke/Association International pour la Recherche et l'Enseignement en Neurosciences criterion vascular dementia Have MRI CT scan ( file since onset symptom AD ) inconsistent probable diagnosis AD Meet Diagnostic Statistical Manual Mental DisordersFifth Edition ( DSMV ) criteria delirium . Have renal impairment define Estimated Glomerular Filtration Rate ( eGFR ) &lt; 45 milliliter per minute per 1.73 square meter ( ml/min/1.73m2 ) Have psychosis nonADassociated etiology ( example , substance abuse diagnosis psychosis prior development AD ) Have significant cardiovascular , respiratory , gastrointestinal , renal , hematologic , oncologic comorbidities could impact patient safety study participation 10 week Have history seizure condition would place patient increase risk seizure . Are , investigator 's judgment , risk suicide , indicate Columbia Suicide Severity Rating Scale ( CSSRS ) Have Fridericia 's correct QT interval ( QTcF ) great ( &gt; ) 450 millisecond ( m ) males 470 m female Use antipsychotic drug intend treat psychosis study . If patient take medication prior study entry , must washout period Are currently enrol clinical trial involve investigational product type medical research judge scientifically medically compatible study Have participate , within last 30 day , clinical trial involve investigational product . If previous investigational product long halflife , least 3 month ( ) must pass In opinion investigator sponsor , unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psychotic Disorders</keyword>
</DOC>